JP2021501789A5 - - Google Patents

Download PDF

Info

Publication number
JP2021501789A5
JP2021501789A5 JP2020524864A JP2020524864A JP2021501789A5 JP 2021501789 A5 JP2021501789 A5 JP 2021501789A5 JP 2020524864 A JP2020524864 A JP 2020524864A JP 2020524864 A JP2020524864 A JP 2020524864A JP 2021501789 A5 JP2021501789 A5 JP 2021501789A5
Authority
JP
Japan
Prior art keywords
alkyl
disease
och
independently
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020524864A
Other languages
English (en)
Japanese (ja)
Other versions
JP7337790B2 (ja
JP2021501789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/058949 external-priority patent/WO2019090069A1/en
Publication of JP2021501789A publication Critical patent/JP2021501789A/ja
Publication of JP2021501789A5 publication Critical patent/JP2021501789A5/ja
Application granted granted Critical
Publication of JP7337790B2 publication Critical patent/JP7337790B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020524864A 2017-11-02 2018-11-02 統合的ストレス経路の調節剤 Active JP7337790B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762580726P 2017-11-02 2017-11-02
US62/580,726 2017-11-02
US201862643059P 2018-03-14 2018-03-14
US62/643,059 2018-03-14
PCT/US2018/058949 WO2019090069A1 (en) 2017-11-02 2018-11-02 Modulators of the integrated stress pathway

Publications (3)

Publication Number Publication Date
JP2021501789A JP2021501789A (ja) 2021-01-21
JP2021501789A5 true JP2021501789A5 (cg-RX-API-DMAC7.html) 2021-12-09
JP7337790B2 JP7337790B2 (ja) 2023-09-04

Family

ID=64572456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524864A Active JP7337790B2 (ja) 2017-11-02 2018-11-02 統合的ストレス経路の調節剤

Country Status (21)

Country Link
US (2) US20200361941A1 (cg-RX-API-DMAC7.html)
EP (1) EP3704094B1 (cg-RX-API-DMAC7.html)
JP (1) JP7337790B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200096918A (cg-RX-API-DMAC7.html)
CN (1) CN112189008A (cg-RX-API-DMAC7.html)
AU (2) AU2018358346A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020008841A2 (cg-RX-API-DMAC7.html)
CA (1) CA3080801A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020001184A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020006227A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200243A (cg-RX-API-DMAC7.html)
EC (1) ECSP20027553A (cg-RX-API-DMAC7.html)
IL (1) IL274368B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004551A (cg-RX-API-DMAC7.html)
PE (1) PE20210040A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020550524A1 (cg-RX-API-DMAC7.html)
RU (1) RU2020117927A (cg-RX-API-DMAC7.html)
SG (1) SG11202003985YA (cg-RX-API-DMAC7.html)
TW (1) TWI818929B (cg-RX-API-DMAC7.html)
UY (1) UY37956A (cg-RX-API-DMAC7.html)
WO (1) WO2019090069A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3512839A4 (en) 2016-09-18 2020-03-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. AGAINST INTERACTION OF YAP1 WITH YCT1 INHIBITORS
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
WO2019178401A1 (en) 2018-03-14 2019-09-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. Yap1 inhibitors that target the interaction of yap1 with oct4
US11166942B2 (en) 2018-06-05 2021-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway
JP2021529814A (ja) * 2018-07-09 2021-11-04 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 化学化合物
TW202545902A (zh) * 2018-10-11 2025-12-01 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
CR20210426A (es) 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
MX2021012904A (es) 2019-04-23 2022-01-18 Evotec Int Gmbh Moduladores de la via de respuesta al estres integrada.
WO2020216766A1 (en) 2019-04-23 2020-10-29 Evotec International Gmbh Modulators of the integrated stress response pathway
AR118836A1 (es) * 2019-04-30 2021-11-03 Calico Life Sciences Llc Moduladores de la vía de tensión integrada
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
IL291665B2 (en) * 2019-09-27 2025-07-01 Univ Texas Inhibitors of receptor interacting protein kinase i for the treatment of disease
CA3162526A1 (en) 2020-01-28 2021-08-05 Christopher John Brown Modulators of the integrated stress response pathway
KR20220151635A (ko) 2020-03-11 2022-11-15 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
WO2021211742A1 (en) * 2020-04-14 2021-10-21 The General Hospital Corporation Use of gcn2 inhibitors in treating mitochondrial myopathies and diseases associated with mitochondrial dysfunction
BR112023003423A2 (pt) * 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
MX2023004677A (es) 2020-10-22 2023-05-24 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
ES2997335T3 (en) 2020-10-22 2025-02-17 Evotec Int Gmbh Modulators of the integrated stress response pathway
TW202241857A (zh) 2020-12-18 2022-11-01 美商戴納立製藥公司 化合物之固體形式
CN118146172B (zh) * 2022-12-06 2026-06-19 帕潘纳(北京)科技有限公司 7-氟-6-氨基-2h-1,4-苯并恶嗪-3(4h)-酮的制备方法
CN121263408A (zh) * 2023-07-14 2026-01-02 深圳众格生物科技有限公司 一种化合物、包含其的药物组合物及其用途
KR102992203B1 (ko) * 2024-02-05 2026-07-20 재단법인 대구경북첨단의료산업진흥재단 신규한 eIF2B 작용제 및 이를 포함하는 대사질환 예방 또는 치료용 조성물
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1026506A (en) * 1962-10-17 1966-04-20 Du Pont Bicyclodiamines and preparation thereof
US3264351A (en) * 1964-07-08 1966-08-02 American Home Prod 1, 4-diaminobicyclo [2.2.2] octanes
US3301827A (en) * 1965-05-07 1967-01-31 Du Pont Polymers from polycyclic reactants having functional substituents on bridgehead carbon atoms
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
TWI538905B (zh) * 2010-12-22 2016-06-21 H 朗德貝克公司 雙環[3.2.1]辛基醯胺衍生物及其用途
WO2014144952A2 (en) * 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
WO2015038778A1 (en) * 2013-09-11 2015-03-19 The Brigham And Women's Hospital, Inc. SUBSTITUTED UREA EIF2α KINASE ACTIVATORS
TWI920577B (zh) * 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808888A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
CN106349130B (zh) * 2016-08-25 2018-01-23 潍坊大有生物化工有限公司 一种新的氟苯尼考的合成方法

Similar Documents

Publication Publication Date Title
JP2021501790A5 (cg-RX-API-DMAC7.html)
JP2021501786A5 (cg-RX-API-DMAC7.html)
JP2021501779A5 (cg-RX-API-DMAC7.html)
JP2021501787A5 (cg-RX-API-DMAC7.html)
JP2021501785A5 (cg-RX-API-DMAC7.html)
JP2021501780A5 (cg-RX-API-DMAC7.html)
JP2021501781A5 (cg-RX-API-DMAC7.html)
JP2021501788A5 (cg-RX-API-DMAC7.html)
RU2020117927A (ru) Модуляторы интегрированного стресса
JP2022530647A5 (cg-RX-API-DMAC7.html)
RU2020117900A (ru) Модуляторы интегрированного стресса
JP7197464B2 (ja) 結合タンパク質-小分子コンジュゲートのev媒介送達
CN115884810A (zh) 作为il-17调节剂的咪唑并哒嗪
JP6159484B2 (ja) グレリンo−アシルトランスフェラーゼ阻害剤
JP7819118B2 (ja) 短鎖デヒドロゲナーゼ活性を調節する組成物及び方法
JP2021519794A (ja) 縮合二環式C5aRアンタゴニストのプロドラッグ
JP2025504859A5 (cg-RX-API-DMAC7.html)
CN109922821A (zh) 使用新型杂合actriib配体陷阱蛋白治疗肌肉萎缩和骨病的方法
CN103214484A (zh) 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
JP2022501060A (ja) 遺伝子の発現のための変異体リバーステトラサイクリントランスアクチベーター
JP2018507899A (ja) 補体関連疾患の治療のための組成物および治療方法
Wen et al. SDF-1α and CXCR4 as therapeutic targets in cardiovascular disease
JP6462151B2 (ja) グレリンo−アシルトランスフェラーゼ阻害剤
CN112194726B (zh) 用于病理性蛋白聚集物清除的嵌合抗原受体及其应用
TW202015693A (zh) 治療pi3k 相關病症之給藥方案